The general manager of Haixiang Pharmaceutical, the world's largest clindamycin manufacturer, resigns

Recently, Haixiang Pharmaceuticals issued a notice that it recently received a written resignation report from director and general manager Yang SiweiYang Siwei applied to resign as a director and general manager of the company for personal reasonsMay 19, Haixiang Pharmaceuticals announced that it had appointed Sun Yang as general manager for the same term as the sixth term of the board of directorsAccording to Article 8 of Haixiang Pharmaceutical's Articles of Association, Sun Yang is also the legal representative of the companyAccording to inquiries, Yang Siwei is a senior economist, has worked in Nanjing Hengxinda Chemical Co., Ltdas general manager, in 2002 into the salt city of Yuhua Chemical Industry Co., Ltd., December 8, 2014 as a director of Haixiang Pharmaceuticals, January 20, 2015 as general manager of Haixiang PharmaceuticalsSun Yang is an engineer, has served as the donggang Group's Donggang fine chemical plant workshop director, production director, factory director, assistant to the group's president, vice presidentHe joined Haixiang Pharmaceuticals in November 2013 and was elected as a director of Haixiang Pharmaceuticals in August 2014, and is currently the Chairman of Haixiang Pharmaceuticals, who is also the Executive Director of Zhejiang Haixiang Chuannan Pharmaceutical Co., Ltd., a wholly owned subsidiary of Haixiang PharmaceuticalsHaixiang Pharmaceutical sits in Taizhou, Zhejiang Province, and is a listed company that mainly produces specialty raw materials, preparations and fine chemicals, dyes and dye intermediates under the Donggang Group, and is one of the top 100 enterprises in the innovation capability of pharmaceutical industry enterprisesHaixiang Pharmaceuticals under the jurisdiction of Taizhou City Forward Chemical Co., Ltd., Zhejiang Haixiang Chuannan Pharmaceutical Co., Ltd., Shanghai Haixiang Pharmaceutical Technology Development Co., Ltd., Zhejiang Haixiang Pharmaceutical Sales Co., Ltd., Taizhou Hongxiang Technology Co., Ltdand Pujian Co., Ltd(Germany), Hong Kong Xiang International Holdings (Hong Kong) Co., LtdAccording to Cypress Blue inquiry, Haixiang pharmaceutical business scope involves four major areas, including pharmaceutical production, pharmaceutical research and development, dye plate, other business, the main business is medicine and dyes two major sectors -sector is mainly engaged in the production and sale of specialty intermediates, apiens and related preparations, while providing international pharmaceutical CDMO/CMO professional services, products covering anti-infection, cardiovascular, psycho
fields, sugar-lowering and immune categories and other fields Haixiang Pharmaceuticals mainly produces antibiotics, cardiovascular, sugar-lowering and other raw materials, refined chemicals and preparations Apiproduct products are a total of Klinmycin hydrochloride, etapenan, Ceresib, Linazine, Liverasaban, Voliconazole, Avibatan and other 24 kinds Among them, the production of more than 70% of exports, of which the production of klinmycin series of stable position in the world's leading position According to Haixiang Pharmaceuticals, it is currently the world's most complete industrial chain, the largest production and marketing of dye activity bright blue KN-R and medicine Klinmycin and Penan products manufacturers, is the only domestic can supply the Penan series of raw materials of one of the in addition to , Haixiang Pharmaceuticals is one of the first companies in China to carry out international CDMO/CMO business, pfizer, Bollinger Ingham, BASF, Sanofi, Novartis, Janssen, Sumitomo Chemical, Desdar, Clariant and other companies are partners According to Haixiang Pharmaceuticals' 2019 annual report, last year the pharmaceutical sector Penan series, Kling series continued to grow, CDMO/CMO cooperative products increased, achieving sales revenue of 1.623 billion yuan, up 10.52 percent year-on-year, net profit of 295 million yuan, up 47.67 percent year-on-year 　　In its annual report, Haixiang Pharmaceuticals also pointed out the opportunities and pressures it may face in the future In recent years, with the gradual landing of the relevant policies of the pharmaceutical system reform, the state's management of the pharmaceutical industry has been increasing The implementation of a series of pharmaceutical policies, such as medical insurance charge, consistency evaluation, two-vote system and collection of normalization, will completely change the existing pattern of the pharmaceutical industry and have a profound impact on the future development of the whole pharmaceutical industry the current medical reform has basically completed the top-level design, into the directional stability period, the quality reduction fee is the main theme of the present and even a long time after for domestic pharmaceutical companies, whether it is generic collection, or innovative drug insurance negotiations, the end result is that enterprises at lower prices in exchange for competitive opportunities set mining makes the competition of generic drugs focus on the cost side, and raw materials is the core of production costs, with high-quality and low-cost raw materials intermediates and raw materials and preparations integrated enterprise competitive advantage is more obvious, will gain greater living space in the current context, pharmaceutical enterprises can strengthen their own research and development capabilities or cooperate with CRO companies to carry out research and development business, product innovation and their own transformation and upgrading; at the same time, Pfizer, Novartis and other international pharmaceutical giants have divested the generic son-into-the-drug business, focusing on innovative drugs The market pattern of generic drugs has ushered in a sea change, whether it is to undertake more CDMO/CMO projects, the integration of international generic assets, or their own preparation products sail out to sea, domestic generic sons will usher in greater opportunities.